Robert J. Motzer, MD, discusses the phase 3 TIVO-1 trial comparing tivozanib with sorafenib in patients with advanced renal cell carcinoma.
Robert J. Motzer, MD, Kidney Cancer section head, genitourinary oncology service and Jack and Dorothy Byrne chair in Clinical Oncology with Memorial Sloan Kettering Cancer Center, discusses the phase 3 TIVO-1 trial comparing tivozanib (Fotivda) with sorafenib (Nexavar) in patients with advanced renal cell carcinoma.
Tivozanib is a highly selective and potent VEGF inhibitor. The agent was evaluated in the large TIVO-1 trial, where it was compared with sorafenib, says Motzer. The TIVO-1 trial reached its primary end point by showing improvement in progression-free survival with tivozanib, although an overall survival benefit was not observed. Additionally, because of the design of the trial, the survival favored sorafenib over tivozanib, explains Motzer.
Tivozanib has remained an investigational agent in the United States, says Motzer. The agent has been approved for use in Europe in select circumstances, concludes Motzer.